Patents by Inventor Chengfei Pu
Chengfei Pu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220348682Abstract: The compositions and methods described herein are directed to treating solid tumor using CAR T therapy. The compositions include CAR comprising an extracellular domain that binds a siglec protein or a receptor that binds the peptide hormone kisspeptin.Type: ApplicationFiled: August 29, 2019Publication date: November 3, 2022Applicants: Innovative Cellular Therapeutics Holdings, Ltd., Innovative Cellular Therapeutics, Inc.Inventors: Lei Xiao, He Sun, Zhiyuan Cao, Wensheng Wang, Chengfei Pu, Li Mao
-
Publication number: 20220339193Abstract: Compositions and methods for enhancing T cell response which increases the efficacy of CAR T cell therapy for treating cancer are described. Embodiments include a modified cell comprising an isolated nucleic acid comprising a first nucleic acid and a second nucleic acid, the first nucleic acid encoding a chimeric antigen receptor (CAR), the second nucleic acid encoding a therapeutic agent comprising at least one of IFN-?, IL-2, IL-6, IL-7, IL-15, IL-17, and IL-23. The modified cell expresses and secretes the therapeutic agent.Type: ApplicationFiled: May 20, 2022Publication date: October 27, 2022Applicant: Innovative Cellular Therapeutics Holdings, Ltd.Inventors: Lei Xiao, Chengfei Pu, Zhiyuan Cao
-
Publication number: 20220265708Abstract: The present disclosure relates to compositions and methods for enhancing T cell response and/or CAR cell expansion in vivo and/or in vitro. For example, a cell may comprise a first chimeric antigen receptor (CAR) and a second CAR, wherein a binding domain of the first CAR binds a first antigen, and a binding domain of the second CAR binds a second antigen. The first antigen is different from the second antigen. In embodiments, the first CAR may recognize a surface molecule of a blood cell.Type: ApplicationFiled: January 10, 2019Publication date: August 25, 2022Applicants: Innovative Cellular Therapeutics, Inc., Innovative Cellular Therapeutics Co., Ltd.Inventors: Lei Xiao, Chengfei Pu, Zhiyuan Cao, Zhao Wu, Li Mao, Mao Bi
-
Publication number: 20220249638Abstract: Embodiments herein relate to humanized CD19 antibodies and disease treatment using the antibodies. For example, a subject having a CD19 positive tumor may be administered a therapeutically effective amount of the humanized antibody.Type: ApplicationFiled: April 21, 2022Publication date: August 11, 2022Applicant: Innovative Cellular Therapeutics Holdings, Ltd.Inventors: Zhao Wu, Zhigang Liu, Lei Xiao, Chengfei Pu, Zhiyuan Cao
-
Publication number: 20220249557Abstract: The present disclosure relates to compositions and methods for enhancing T cell response in vivo. For example, a method of enhancing T cell response in a subject or treating a subject having cancer, the method comprising: administering an effective amount of a composition comprising modified cells to the subject having a form of cancer associated with or expressing an antigen, for example, a solid tumor antigen; and administering (1) a nucleic acid encoding the antigen, (2) additional modified cells comprising the nucleic acid or the antigen, or (3) microorganisms, for example cold viruses, comprising the nucleic acid or the antigen. In embodiments, the modified cells comprise mixed cells targeting a solid tumor antigen and a white blood cell (WBC) antigen. In embodiments, the modified cells comprise a dominant negative form of an immune checkpoint molecule (e.g., PD-1). In embodiments, the modified cells comprise an exogenous polynucleotide encoding a therapeutic agent, such as IL-12 and IFN?.Type: ApplicationFiled: February 4, 2022Publication date: August 11, 2022Applicants: Innovative Cellular Therapeutics Holdings, Ltd., Innovative Cellular Therapeutics, Inc.Inventors: Yang Li, Zhiyuan Cao, Wei Ding, Xianyang Jiang, Chengfei Pu, Le Tian, Christopher Ballas, Zhao Wu, Lei Xiao
-
Patent number: 11364289Abstract: Embodiments herein relate to humanized CD19 antibodies and disease treatment using the antibodies. For example, a subject having a CD19 positive tumor may be administered a therapeutically effective amount of the humanized antibody.Type: GrantFiled: October 11, 2019Date of Patent: June 21, 2022Assignee: Innovative Cellular Therapeutics Holdings, Ltd.Inventors: Zhao Wu, Zhigang Liu, Lei Xiao, Chengfei Pu, Zhiyuan Cao
-
Publication number: 20220096546Abstract: The present disclosure relates to compositions and methods for enhancing T cell response and/or CAR cell expansion and/or maintenance in vivo and/or in vitro. For example, a method of enhancing T cell-based therapy comprises administering a mixed population of T cells comprising modified T cells comprising a first chimeric antigen receptor (CAR) and modified T cells comprising a second CAR, wherein a binding domain of the first CAR binds a first antigen, and a binding domain of the second CAR binds a second antigen. The first antigen is different from the second antigen. In embodiments, the first CAR binds a surface molecule or antigen of a white blood cell.Type: ApplicationFiled: January 10, 2020Publication date: March 31, 2022Applicant: Innovative Cellular Therapeutics Holdings, Ltd.Inventors: Lei Xiao, Chengfei Pu, Zhiyuan Cao
-
Patent number: 11235004Abstract: Embodiments described herein relate to compositions including genetically modified CAR cells and uses thereof for treating cancer. Some embodiments of the present disclosure relate to compositions and methods for T cell response enhancement and/or CAR cell preparation. For example, a method may include obtaining cells comprising a CAR and culturing the cells in the presence of an agent that is recognized by the extracellular domain of the CAR.Type: GrantFiled: June 29, 2018Date of Patent: February 1, 2022Assignee: Innovative Cellular Therapeutics Holdings, Ltd.Inventors: Lei Xiao, Chengfei Pu, Zhiyuan Cao, Zhao Wu
-
Publication number: 20220000921Abstract: Compositions and methods for enhancing T cell response which increases the efficacy of CAR T cell therapy for treating cancer are described. Embodiments include a modified cell comprising an isolated nucleic acid comprising a first nucleic acid and a second nucleic acid, the first nucleic acid encoding a chimeric antigen receptor (CAR), the second nucleic acid encoding a therapeutic agent comprising at least one of IFN-y, IL-2, IL-6, IL-7, IL-15, IL-17, and IL-23. The modified cell expresses and secretes the therapeutic agent.Type: ApplicationFiled: November 20, 2019Publication date: January 6, 2022Applicant: Innovative Cellular Therapeutics Holdings, Ltd.Inventors: Lei Xiao, Chengfei Pu, Zhiyuan Cao
-
Publication number: 20210379149Abstract: Embodiments relate to a method for increasing or maintaining a population of memory T-cells. The method includes introducing T-cells with a nucleic acid encoding a chimeric antigen receptor (CAR), wherein the CAR includes an extracellular domain, a transmembrane domain, and an intracellular domain, and the extracellular domain binds an antigen; introducing into the T-cells a nucleic acid encoding a modified PD-1, wherein the modified PD-1 lacks a functional PD-1 intracellular domain; and administering an effective amount of a composition comprising the T-cells to a subject having cancer.Type: ApplicationFiled: October 25, 2019Publication date: December 9, 2021Applicants: Innovative Cellular Therapeutics Holdings, Ltd., Innovative Cellular Therapeutics, Inc.Inventors: Chengfei Pu, Zhiyuan Cao, He Sun, Zhao Wu, Lei Xiao
-
Publication number: 20210371492Abstract: The present disclosure relates to compositions and methods of treating a subject having digestive tract cancer, the method comprising: administering an effective amount of a composition to the subject, the composition comprising a first population of cells comprising a first CAR binding a first antigen, and a second population of cells comprising a second CAR binding GCC, wherein the first antigen comprises a cell surface molecule of a white blood cell (WBC).Type: ApplicationFiled: May 26, 2021Publication date: December 2, 2021Applicants: Innovative Cellular Therapeutics Holdings, Ltd., Innovative Cellular Therapeutics, Inc.Inventors: Lei Xiao, Xiaogang Shen, Wensheng Wang, Dongqi Chen, Beibei Jia, Chengfei Pu, Le Tian
-
Publication number: 20210347893Abstract: The present disclosure relates to a modified cell comprising a polynucleotide encoding a secretable scFv binding SIGLEC-15 and/or encoding a dominant negative form of CD44. In embodiments, the modified cell further comprises an antigen-binding molecule, which for example, is a CAR comprising an antigen-binding domain, a transmembrane domain, and an intracellular signaling domain.Type: ApplicationFiled: July 22, 2021Publication date: November 11, 2021Applicant: Innovative Cellular Therapeutics Holdings, Ltd.Inventors: Zhiyuan Cao, Chengfei Pu, Lei Xiao
-
Patent number: 11161913Abstract: The compositions and methods described herein are directed to treating solid tumor using CAR T therapy. The compositions include CAR comprising an extracellular domain that binds a siglec protein or a receptor that binds the peptide hormone kisspeptin.Type: GrantFiled: April 1, 2021Date of Patent: November 2, 2021Assignees: Innovative Cellular Therapeutics Holdings, Ltd., Innovative Cellular Therapeutics, Inc.Inventors: Lei Xiao, He Sun, Zhiyuan Cao, Wensheng Wang, Chengfei Pu, Li Mao
-
Patent number: 11104732Abstract: The present disclosure relates to a modified cell comprising a polynucleotide encoding a secretable scFv binding SIGLEC-15 and/or encoding a dominant negative form of CD44. In embodiments, the modified cell further comprises an antigen-binding molecule, which for example, is a CAR comprising an antigen-binding domain, a transmembrane domain, and an intracellular signaling domain.Type: GrantFiled: April 23, 2020Date of Patent: August 31, 2021Inventors: Zhiyuan Cao, Chengfei Pu, Lei Xiao
-
Publication number: 20210252059Abstract: The present disclosure relates to compositions and methods for treating cancer. For example, a modified cell may include a polynucleotide comprising an NFAT promoter, a nucleotide sequence encoding therapeutic agent, and a nucleotide sequence encoding a VHL-interaction domain of HIF1?, wherein the therapeutic agent comprises, for example, IL-12, IL-6, and/or IFN?.Type: ApplicationFiled: February 11, 2021Publication date: August 19, 2021Applicants: Innovative Cellular Therapeutics Holdings, Ltd., Innovative Cellular Therapeutics, Inc.Inventors: Chengfei Pu, Zhiyuan Cao, Zhao Wu, Lei Xiao
-
Publication number: 20210230308Abstract: The compositions and methods described herein are directed to treating solid tumor using CAR T therapy. The compositions include CAR comprising an extracellular domain that binds a siglec protein or a receptor that binds the peptide hormone kisspeptin.Type: ApplicationFiled: April 1, 2021Publication date: July 29, 2021Applicants: Innovative Cellular Therapeutics Holdings, Ltd., Innovative Cellular Therapeutics, Inc.Inventors: Lei Xiao, He Sun, Zhiyuan Cao, Wensheng Wang, Chengfei Pu, Li Mao
-
Publication number: 20210161961Abstract: Compositions and methods for enhancing T cell response which increases the efficacy of CAR T cell therapy for treating cancer are described. Embodiments include a modified cell comprising an isolated nucleic acid comprising a first nucleic acid and a second nucleic acid, the first nucleic acid encoding a chimeric antigen receptor (CAR), the second nucleic acid encoding a therapeutic agent comprising at least one of IFN-?, IL-2, IL-6, IL-7, IL-15, IL-17, and IL-23. The modified cell expresses and secretes the therapeutic agent.Type: ApplicationFiled: January 8, 2021Publication date: June 3, 2021Applicant: Innovative Cellular Therapeutics Holdings, Ltd.Inventors: Lei Xiao, Chengfei Pu, Zhiyuan Cao, He Sun
-
Publication number: 20210137983Abstract: The present disclosure relates to compositions and methods for enhancing NK cell response and/or maintenance in vivo and/or in vitro. For example, a method of enhancing NK cell-based therapy comprises administering a mixed population of NK cells comprising modified NK cells comprising a first chimeric antigen receptor (CAR) and modified NK cells comprising a second CAR, wherein a binding domain of the first CAR binds a first antigen, and a binding domain of the second CAR binds a second antigen. The first antigen is different from the second antigen. In embodiments, the first CAR binds a surface molecule or antigen of a white blood cell.Type: ApplicationFiled: November 6, 2020Publication date: May 13, 2021Applicants: Innovative Cellular Therapeutics Holdings, Ltd., Innovative Cellular Therapeutics, Inc.Inventors: Lei Xiao, Chengfei Pu, Zhiyuan Cao, Le Tian
-
Publication number: 20210122802Abstract: Embodiments relate to a modified cell engineered to comprise a modified TCR-CD3 complex, wherein the CD3?, ?-chain, CD3?, and/or CD3? chains of the modified TCR-CD3 complex are linked to one or more co-stimulatory signaling domains.Type: ApplicationFiled: October 22, 2020Publication date: April 29, 2021Applicants: Innovative Cellular Therapeutics Holdings, Ltd., Innovative Cellular Therapeutics, Inc.Inventors: Chengfei Pu, Dongqi Chen, Xiaogang Shen
-
Publication number: 20210100841Abstract: The present disclosure relates to compositions and methods for enhancing T cell response and/or CAR cell expansion and/or maintenance in vivo and/or in vitro. For example, in a method of in vivo cell expansion, the method comprises administering an effective amount of cells comprising an antigen binding molecule to a subject; and administering an effective amount of presenting cells expressing a solid tumor antigen that the binding molecule binds.Type: ApplicationFiled: August 21, 2020Publication date: April 8, 2021Applicants: Innovative Cellular Therapeutics Holdings, Ltd., Innovative Cellular Therapeutics, Inc.Inventors: Lei Xiao, Chengfei Pu, Zhiyuan Cao, Zhao Wu, Le Tian